Are you or someone you know struggling with memory problems? We know how challenging that can be, and we’re excited to share an opportunity that could make a difference. The TargetTau-1 Clinical Study is beginning, and we’re looking for participants to help test a promising new treatment.
About the TargetTau-1 Study
This study is designed to evaluate a new medication that may help people who are in the early stages of Alzheimer’s disease (AD). Memory problems, confusion, and difficulty with daily tasks are common symptoms of AD, and this treatment aims to slow down or even halt these issues.
How Does the New Treatment Work?
To understand how this new treatment might work, it’s helpful to know a little about two key proteins in the brain: amyloid and tau.
Amyloid: This protein can build up in the brain, forming sticky plaques that interfere with how brain cells communicate. For many years, researchers have focused on amyloid as a key player in Alzheimer’s disease.
Tau: Unlike amyloid, tau plays a different role in the brain. In a healthy brain, tau helps maintain the structure of brain cells. But in Alzheimer’s disease, tau can become tangled, leading to the breakdown of these cells and causing memory loss.
The new treatment in this study targets tau. It works by binding to the abnormal tau protein, marking it so that the body’s immune system can recognize and clear it. By helping to reduce the amount of tau tangles in the brain, this treatment may protect brain cells and slow down memory loss.
Study Design: How It Works
Randomized: Participants will be randomly assigned to one of two groups. One group will receive the new treatment, while the other will receive a placebo—a substance with no active ingredients. This randomization helps ensure that the study results are unbiased.
Double-blind: In this type of study, neither the participants nor the researchers know who is receiving the actual treatment and who is receiving the placebo. This method ensures that the outcomes are measured objectively.
Multicenter: The study will take place at multiple locations, allowing a diverse group of participants to enroll. This also helps the researchers gather a wide range of data to determine the treatment’s effectiveness.
Who Can Participate?
You may qualify for the TargetTau-1 study if you:
- Are between 50-80 years old
- Have a diagnosis of mild cognitive impairment due to Alzheimer’s disease, or have mild Alzheimer’s dementia
- Have a study partner with whom you spend at least 8 hours per week (such as a spouse, friend, or an adult child) who can attend some study visits with you during the study and provide follow-up information
The study doctor will also check other eligibility requirements.
What to Expect if You Join
Participation in the TargetTau-1 study lasts about 2 years and requires regular visits to the research clinic to receive the study drug and monitor your health and AD status. If you decide to take part in the study, all study-related drugs and procedures will be provided to you at no cost. Participation is voluntary, and you can leave the study at any point.
Why Participate?
Be Part of Potentially Groundbreaking Research: By participating in the TargetTau-1 study, you are contributing to vital research that could lead to the development of a new treatment for Alzheimer’s disease. Even though the study is placebo-controlled, your involvement is crucial in helping determine if this new approach is effective in slowing down or improving memory loss.
Contribute to Scientific Research: By joining this trial, you’ll be contributing to crucial research that could help countless people in the future. Your participation could be a key part of finding a new treatment for Alzheimer’s disease.
Receive Expert Care: Throughout the study, you will be closely monitored by a team of healthcare professionals. This means you’ll receive regular check-ups and support to ensure your well-being during the trial.
Interested in Learning More?
If you or someone you know is interested in participating or would like more information, please contact us at 615.550.1807. We’re here to answer any questions and guide you through the process.
Joining the TargetTau-1 study could be a significant step forward—not only for you but for many others who are affected by memory problems. Together, we can contribute to a potential breakthrough in the treatment of Alzheimer’s disease.